Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Operating Expenses (2017 - 2025)

Crinetics Pharmaceuticals has reported Operating Expenses over the past 9 years, most recently at $139.8 million for Q4 2025.

  • Quarterly results put Operating Expenses at $139.8 million for Q4 2025, up 47.58% from a year ago — trailing twelve months through Dec 2025 was $524.5 million (up 54.3% YoY), and the annual figure for FY2025 was $524.5 million, up 54.3%.
  • Operating Expenses for Q4 2025 was $139.8 million at Crinetics Pharmaceuticals, down from $142.7 million in the prior quarter.
  • Over the last five years, Operating Expenses for CRNX hit a ceiling of $142.7 million in Q3 2025 and a floor of $22.9 million in Q1 2021.
  • Median Operating Expenses over the past 5 years was $56.7 million (2023), compared with a mean of $68.6 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 66.68% in 2022 and later grew 24.14% in 2023.
  • Crinetics Pharmaceuticals' Operating Expenses stood at $32.0 million in 2021, then soared by 50.99% to $48.3 million in 2022, then increased by 29.82% to $62.7 million in 2023, then soared by 51.21% to $94.7 million in 2024, then skyrocketed by 47.58% to $139.8 million in 2025.
  • The last three reported values for Operating Expenses were $139.8 million (Q4 2025), $142.7 million (Q3 2025), and $130.1 million (Q2 2025) per Business Quant data.